Measles and rubella antibody status in children after treatment for acute lymphoblastic leukemia

Jornal de Pediatria

Volumn 82, Issue 6, 2006, Pages 481-484

  Volc, Sáhlua M ^a   Almeida, Maria T A ^a   Abadi, Márcia D ^a   Cornacchioni, Ana Lucia ^a   Odone Filho, Vicente ^a   Cristofani, Lílian M ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Hospital Das Clínicas da Faculdade de Medicina da Universidade de São Paulo ^*  (Brazil)

Author keywords

Chemotherapy; Immunization; Immunosuppression

Indexed keywords

MEASLES ANTIBODY; MEASLES VACCINE; RUBELLA ANTIBODY; RUBELLA VACCINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ANAMNESIS; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE STATUS; MEASLES; RUBELLA; SEROLOGY; VACCINATION;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNE TOLERANCE; IMMUNIZATION SCHEDULE; LEUKEMIA, LYMPHOCYTIC, ACUTE; MEASLES; MEASLES VACCINE; RUBELLA; RUBELLA VACCINE; STATISTICS, NONPARAMETRIC;

EID: 33845487126     PISSN: 00217557     EISSN: None     Source Type: Journal    
DOI: 10.2223/JPED.1532     Document Type: Article

References (13)

1. Smith S, Schiffman G, Karayalcin G, Bonagura V. Immunodeficiency in long-term survivors of acute lymphoblastic leukemia treated with BFM therapy. J Pediatr 1995;127:68-75.
2. MacLennan IC, Liu YJ, Johnson GD. Maturation and dispersal of B-cell clones during T cell-dependent antibody responses. Immunol Rev. 1992;126:143-61.
3. Alanko S, Pelliniemi TT, Salmi TT. Recovery of blood B-lymphocytes and serum immunoglobulins after chemotherapy for childhood acute lymphoblastic leukemia. Cancer. 1992;69:1481-6.
4. Forghani B, Schmidt NJ. Antigen requirements, sensitivity and specificity of enzyme immunoassays for measles and rubella viral antibodies. J Clin Microbiol. 1979;9:657-64.
5. de Souza VA, Pannuti CS, Sumita LM, de Andrade Junior HF. Enzyme linked immunosorbent assay - IgG antibody avidity test for single sample serologic evaluation of measles vaccines. J Med Virol. 1997;52:275-9.
6. Weckx LY, Carvalho ES. Calendário vacinal: dinâmica e atualização. J Pediatr (Rio J). 1999;75(Supl 1):s149-54.
7. Feldman S, Andrew M, Norris M, McIntire B, Iyer R. Decline in rates seropositivity for measles, mumps, and rubella antibodies among previously immunized children treated for acute leukemia. Clin Infect Dis. 1998;27:388-90.
8. Nilsson A, De Milito A, Engstrom P, Nordin M, Narita M, Grillner L, et al. Current chemotherapy protocols for childhood acute lymphoblastic leukemia induce loss of humoral immunity to viral vaccination antigens. Pediatrics. 2002;109:e91.
9. Brodtman DH, Rosenthal DW, Redner A, Lanzkowski P, Bonagura VR. Immunodeficiency in children with acute lymphoblastic leukemia after completion of modern aggressive chemotherapeutic regimens. J Pediatr. 2005;146:654-61.
10. Brasil, Ministério da Saúde, Fundação Nacional da Saúde, CENEPI. Nota técnica "saiba mais" - Sarampo. Vigilância Epidemiológica - Imunizações. 09/05/2002.
11. Ek T, Mellander L, Andersson B, Abrahamsson J. Immune reconstitution after childhood acute lymphoblastic leukemia is most severely affected in the high risk group. Pediatr Blood Cancer. 2005;44:461-8.
12. Ljungman P, Cordonnier C, de Bock R, Einsele H, Engelhard D, Grundy J, et al. Immunisations after bone marrow transplantation: results of a European survey and recommendations from the infectious diseases working party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1995;15:455-60.
13. Mahajan A, English MW, Jenney ME, Foot A. Survey of immunisation practices in the United Kingdom during and following completion of anti-cancer chemotherapy in children. Med Pediatr Oncol. 2003;40:270-1.